Phenanthriplatin

Phenanthriplatin

Phenanthriplatin is a platinum-based anticancer drug that is part of the platinum compounds family. It was developed as a potential alternative to the widely used cisplatin, carboplatin, and oxaliplatin.

History

Phenanthriplatin was first synthesized and studied by researchers at Massachusetts Institute of Technology (MIT) in 2012. The research was led by Stephen J. Lippard, a renowned chemist known for his work on platinum-based anticancer drugs.

Structure and Mechanism of Action

Phenanthriplatin is a monofunctional platinum(II) complex, which means it binds to DNA at only one site. This is in contrast to cisplatin and its derivatives, which are bifunctional and bind to DNA at two sites. The structure of phenanthriplatin includes a phenanthridine ligand, which is responsible for its unique properties.

The mechanism of action of phenanthriplatin involves forming a covalent bond with the DNA, causing it to bend and distorting its normal shape. This distortion interferes with the DNA's ability to replicate and transcribe, which in turn inhibits the growth and proliferation of cancer cells.

Efficacy and Side Effects

In preclinical studies, phenanthriplatin has shown to be up to 40 times more potent than cisplatin. It has also demonstrated activity against cancer cells that are resistant to cisplatin.

Like all platinum-based anticancer drugs, phenanthriplatin can cause side effects. These can include nausea, vomiting, kidney damage, and neurotoxicity. However, the severity and incidence of these side effects can vary depending on the specific drug and the patient's individual response.

Current Status

As of now, phenanthriplatin is still in the experimental stage and has not been approved for use in humans. Further research and clinical trials are needed to fully understand its efficacy and safety profile.

See Also

• Platinum-based antineoplastic
• Cisplatin
• Carboplatin
• Oxaliplatin